NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/28/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,576.6 mln
Float29.72 mln
Earnings Date11/18/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
27
/ 100
Underperforming
Debt / Equity
-59.02
Negative equity
ROE
-374
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Celcuity is a Minneapolis-based clinical-stage company founded in 2011 that develops precision treatments for solid tumors. Its primary focus is Gedatolisib, a drug designed to block key molecular pathways that drive advanced breast cancer and metastatic prostate cancer. The company holds a licensing agreement with Pfizer covering the development and commercialization of this drug candidate.
